Fondazione S. D. N., Istituto di Ricerca Diagnostica e Nucleare, Via Pansini 5, 80131, Napoli, Italy.
Radiol Med. 2010 Mar;115(2):215-24. doi: 10.1007/s11547-009-0491-6. Epub 2009 Dec 16.
The authors sought to evaluate whether the reacquisition of images 3 h after administration of radiotracer improves the sensitivity of fluorine-18 fluorodeoxyglucose positron emission tomography computed tomography ([(18)F]-FDG PET/CT) in patients with suspicious breast lesions.
Forty-eight patients with 59 breast lesions underwent an [(18)F]-FDG PET/CT study in the prone position with a dual-time-point acquisition performed in the early phase 1 h after FDG administration (PET-1) and in the delayed phase 3 h after FDG administration (PET-2). Both examinations were evaluated qualitatively and semiquantitatively with calculation of the mean percentage variation of the standard uptake values (Delta% SUV(max)) between PET-1 and PET-2. All lesions with an SUV(max) >or=2.5 at PET-1 or a reduction in SUV between PET-1 and PET-2 were considered benign. The definitive histopathological diagnosis was available for all patients included in the study.
The dual-time-point acquisition of [(18)F]-FDG PET/CT displayed an accuracy of 85% for lesions with an SUV(max) >or=2.5 and/or positive Delta% SUV(max), with sensitivity and specificity values of 81% and 100% compared with 69%, 63% (both p<0.001) and 100% (p=n.s.), respectively, for the single-time-point acquisition. Malignant lesions showed an increase in FDG uptake between PET-1 and PET-2, with a Delta% SUV(max) of 10+/-7 (p<0.04). In contrast, benign lesions showed a decrease in SUV between PET-1 and PET-2, with a Delta% SUV(max) of -21+/-7 (p<0.001).
The delayed repeat acquisition of PET images improves the accuracy of [(18)F]-FDG PET/CT in patients with suspicious breast lesions with respect to the single-time-point acquisition. In addition, malignant breast lesions displayed an increase in FDG uptake over time, whereas benign lesions showed a reduction. These variations in FDG uptake between PET-1 and PET-2 are a reliable parameter that can be used for differentiating between benign and malignant breast lesions.
作者旨在评估在怀疑有乳腺病变的患者中，放射性示踪剂给药后 3 小时再次采集图像是否能提高氟-18 氟代脱氧葡萄糖正电子发射断层扫描计算机断层扫描 ([（18）F]-FDG PET/CT）的灵敏度。
48 例 59 个乳腺病变患者行 [（18）F]-FDG PET/CT 检查，在俯卧位进行双时相采集，在 FDG 给药后 1 小时的早期阶段（PET-1）和 FDG 给药后 3 小时的延迟阶段（PET-2）进行。对两次检查均进行定性和半定量评估，计算标准摄取值（SUV）的平均百分比变化（Delta% SUV(max)）。所有在 PET-1 时 SUV(max) >或=2.5 或 SUV 在 PET-1 和 PET-2 之间下降的病变均被认为是良性的。所有纳入研究的患者均获得了明确的组织病理学诊断。
[（18）F]-FDG PET/CT 的双时相采集对于 SUV(max) >或=2.5 和/或阳性 Delta% SUV(max)的病变的准确性为 85%，与单次采集相比，其敏感性和特异性值分别为 81%和 100%，而 69%、63%（均 p<0.001）和 100%（p=n.s.）。恶性病变在 PET-1 和 PET-2 之间的 FDG 摄取增加，Delta% SUV(max)为 10+/-7（p<0.04）。相反，良性病变在 PET-1 和 PET-2 之间的 SUV 减少，Delta% SUV(max)为 -21+/-7（p<0.001）。
对于怀疑有乳腺病变的患者，与单次采集相比，重复采集 PET 图像可提高 [（18）F]-FDG PET/CT 的准确性。此外，恶性乳腺病变随时间显示 FDG 摄取增加，而良性病变显示摄取减少。在 PET-1 和 PET-2 之间 FDG 摄取的这些变化是区分良性和恶性乳腺病变的可靠参数。
